Roivant Sciences News - July 2026

🟢 Roivant Sciences is trading 4.9% up today after Q4 earnings beat and $770M Moderna settlement gain

Roivant Sciences is trading at $36.20 (+4.91%) in pre-market action after fiscal Q4 2026 results significantly beat analyst expectations due to a major...

Roivant's Genevant Sues Pfizer Globally, Escalating Multi-Billion Dollar Patent Fight

Roivant Sciences' subsidiary Genevant Sciences and Arbutus Biopharma filed three new patent infringement lawsuits against Pfizer and BioNTech. These filings in...